ECSP10010555A - Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona - Google Patents
Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-onaInfo
- Publication number
- ECSP10010555A ECSP10010555A EC2010010555A ECSP10010555A ECSP10010555A EC SP10010555 A ECSP10010555 A EC SP10010555A EC 2010010555 A EC2010010555 A EC 2010010555A EC SP10010555 A ECSP10010555 A EC SP10010555A EC SP10010555 A ECSP10010555 A EC SP10010555A
- Authority
- EC
- Ecuador
- Prior art keywords
- quinolin
- piperazin
- fluoro
- amino
- methyl
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical class C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formas cristalinas o polimorfos de las sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1H-bencimidazol-2-il]-quinolin-2(1H)-ona, asi como metodos para la elaboracion de las mismas, composiciones farmaceuticas que comprenden las mismas, y metodos de tratamiento utilizando las mismas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3774608P | 2008-03-19 | 2008-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010555A true ECSP10010555A (es) | 2010-11-30 |
Family
ID=40622140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010555A ECSP10010555A (es) | 2008-03-19 | 2010-10-19 | Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8563556B2 (es) |
| EP (1) | EP2257544B1 (es) |
| JP (1) | JP2011515370A (es) |
| KR (1) | KR20100137517A (es) |
| CN (1) | CN101970425B (es) |
| AR (1) | AR070924A1 (es) |
| AU (1) | AU2009227003B2 (es) |
| BR (1) | BRPI0909762A2 (es) |
| CA (1) | CA2718076A1 (es) |
| CL (1) | CL2009000651A1 (es) |
| CO (1) | CO6321253A2 (es) |
| EC (1) | ECSP10010555A (es) |
| IL (1) | IL208020A0 (es) |
| MA (1) | MA32230B1 (es) |
| MX (1) | MX2010010152A (es) |
| MY (1) | MY150554A (es) |
| NZ (2) | NZ587829A (es) |
| PE (1) | PE20091628A1 (es) |
| PH (2) | PH12012502568A1 (es) |
| RU (1) | RU2497820C2 (es) |
| SG (1) | SG188919A1 (es) |
| TW (1) | TWI426072B (es) |
| WO (1) | WO2009115562A2 (es) |
| ZA (1) | ZA201006263B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
| WO2011128405A1 (en) | 2010-04-16 | 2011-10-20 | Novartis Ag | Combination of organic compounds |
| US8741903B2 (en) | 2010-04-16 | 2014-06-03 | Novartis Ag | Organic compound for use in the treatment of hepatocellular cancer (HCC) |
| AR081776A1 (es) | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
| US20130345234A1 (en) | 2011-03-17 | 2013-12-26 | Humphrey Athelstan Roy Gardner | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects |
| US20150182525A1 (en) | 2011-05-19 | 2015-07-02 | Novartis Ag | 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma |
| JP2014526506A (ja) | 2011-09-15 | 2014-10-06 | ノバルティス アーゲー | 中等度肝障害患者の癌治療における4−アミノ−5−フルオロ−3−[6−(4−メチルピペラジン−1−イル)−1h−ベンゾイミダゾール−2−イル]−1h−キノリン−2−オンの使用 |
| WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| MX2014009303A (es) | 2012-01-31 | 2014-10-14 | Novartis Ag | Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer. |
| AU2013289175A1 (en) | 2012-07-11 | 2015-01-22 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0113757B8 (pt) * | 2000-09-11 | 2017-11-07 | Chiron Corp | derivados de quinolinona como inibidores de tirosina quinase |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| EP2573079A3 (en) * | 2002-08-23 | 2015-03-11 | Novartis AG | Benzimidazole quinolinones and uses thereof |
| US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| CN100377709C (zh) * | 2002-11-13 | 2008-04-02 | 希龙公司 | 受体酪氨酸激酶抑制剂的制药用途及相关检测方法 |
| SG148864A1 (en) | 2002-11-13 | 2009-01-29 | Chiron Corp | Methods of treating cancer and related methods |
| JP4823914B2 (ja) * | 2003-11-07 | 2011-11-24 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Fgfr3の阻害および多発性骨髄腫の治療 |
| EP1718306A2 (en) * | 2004-02-20 | 2006-11-08 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
| DK1845990T3 (da) * | 2005-01-27 | 2012-01-02 | Novartis Vaccines & Diagnostic | Behandling af metastaserede tumorer |
| EP2270000B1 (en) * | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| KR20080074143A (ko) * | 2005-11-29 | 2008-08-12 | 노파르티스 아게 | 퀴놀리논 제제 |
| AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
-
2009
- 2009-03-17 AR ARP090100957A patent/AR070924A1/es unknown
- 2009-03-17 PE PE2009000395A patent/PE20091628A1/es not_active Application Discontinuation
- 2009-03-18 JP JP2011500221A patent/JP2011515370A/ja active Pending
- 2009-03-18 CL CL2009000651A patent/CL2009000651A1/es unknown
- 2009-03-18 TW TW098108804A patent/TWI426072B/zh not_active IP Right Cessation
- 2009-03-18 NZ NZ587829A patent/NZ587829A/xx not_active IP Right Cessation
- 2009-03-18 RU RU2010142396/04A patent/RU2497820C2/ru not_active IP Right Cessation
- 2009-03-18 US US12/922,213 patent/US8563556B2/en not_active Expired - Fee Related
- 2009-03-18 BR BRPI0909762A patent/BRPI0909762A2/pt not_active IP Right Cessation
- 2009-03-18 KR KR1020107023196A patent/KR20100137517A/ko not_active Ceased
- 2009-03-18 SG SG2013020011A patent/SG188919A1/en unknown
- 2009-03-18 CN CN200980108402.0A patent/CN101970425B/zh not_active Expired - Fee Related
- 2009-03-18 MY MYPI20104156 patent/MY150554A/en unknown
- 2009-03-18 EP EP09721534.7A patent/EP2257544B1/en active Active
- 2009-03-18 NZ NZ600887A patent/NZ600887A/xx not_active IP Right Cessation
- 2009-03-18 WO PCT/EP2009/053222 patent/WO2009115562A2/en not_active Ceased
- 2009-03-18 CA CA2718076A patent/CA2718076A1/en not_active Abandoned
- 2009-03-18 MX MX2010010152A patent/MX2010010152A/es not_active Application Discontinuation
- 2009-03-18 AU AU2009227003A patent/AU2009227003B2/en not_active Ceased
-
2010
- 2010-09-01 ZA ZA2010/06263A patent/ZA201006263B/en unknown
- 2010-09-06 IL IL208020A patent/IL208020A0/en not_active IP Right Cessation
- 2010-10-15 MA MA33250A patent/MA32230B1/fr unknown
- 2010-10-19 EC EC2010010555A patent/ECSP10010555A/es unknown
- 2010-10-19 CO CO10129430A patent/CO6321253A2/es not_active Application Discontinuation
-
2012
- 2012-12-26 PH PH12012502568A patent/PH12012502568A1/en unknown
- 2012-12-26 PH PH12012502569A patent/PH12012502569A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009227003A1 (en) | 2009-09-24 |
| NZ600887A (en) | 2013-10-25 |
| BRPI0909762A2 (pt) | 2018-04-03 |
| US20110021536A1 (en) | 2011-01-27 |
| MA32230B1 (fr) | 2011-04-01 |
| EP2257544A2 (en) | 2010-12-08 |
| WO2009115562A2 (en) | 2009-09-24 |
| HK1147492A1 (en) | 2011-08-12 |
| SG188919A1 (en) | 2013-04-30 |
| RU2497820C2 (ru) | 2013-11-10 |
| AU2009227003B2 (en) | 2013-03-14 |
| AR070924A1 (es) | 2010-05-12 |
| IL208020A0 (en) | 2010-12-30 |
| PH12012502568A1 (en) | 2014-10-27 |
| PH12012502569A1 (en) | 2015-09-21 |
| TW201000463A (en) | 2010-01-01 |
| CL2009000651A1 (es) | 2010-07-19 |
| MX2010010152A (es) | 2010-10-25 |
| CN101970425B (zh) | 2014-04-16 |
| RU2010142396A (ru) | 2012-04-27 |
| TWI426072B (zh) | 2014-02-11 |
| ZA201006263B (en) | 2011-05-25 |
| MY150554A (en) | 2014-01-30 |
| CN101970425A (zh) | 2011-02-09 |
| KR20100137517A (ko) | 2010-12-30 |
| US8563556B2 (en) | 2013-10-22 |
| EP2257544B1 (en) | 2014-12-03 |
| WO2009115562A3 (en) | 2009-11-26 |
| JP2011515370A (ja) | 2011-05-19 |
| CO6321253A2 (es) | 2011-09-20 |
| NZ587829A (en) | 2012-08-31 |
| CA2718076A1 (en) | 2009-09-24 |
| PE20091628A1 (es) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6321253A2 (es) | Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4- amino-5- fluoro-3-[5-(4-metil-piperazin-1-il)1h-bencimidazol-2-il]-quinolin-2(1h)-ona | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| ECSP11011011A (es) | Derivados de acido 1-amino-2-ciclobutiletilborónico | |
| DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CR20110230A (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
| CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
| ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
| NI201100063A (es) | Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38. | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CU20120034A7 (es) | Compuestos y composiciones como inhibidores de cinasa de proteína | |
| UY31860A (es) | Piridinas de tiazolo como inhibidoras de la adn girasa | |
| CU24052B1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos | |
| MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
| CL2007003671A1 (es) | Metodo para la preparacion de derivados del acido 2-amino-5-cianobenzoico, utiles como intermediarios para la preparacion de las correspondientes diamidas cianoantranilicas. | |
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| ECSP078030A (es) | Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona | |
| MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
| BR112012031981A2 (pt) | composição aquosa de ingrediente ativo, processo, uso, método para controlar fungos fitopatogênicos e semente | |
| UY33549A (es) | Quinolil aminas como agentes inhibidores de las quinasas | |
| UY34070A (es) | Método y composición para tratamiento de semillas. | |
| DK3083627T3 (da) | [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis |